One Health Biosensing: Company Profile

Background

Company Overview

One Health Biosensing is a health-tech startup headquartered in New York, NY, specializing in the development of innovative continuous glucose monitoring (CGM) solutions. The company aims to revolutionize diabetes management by providing accessible, affordable, and user-friendly CGM devices. Founded in February 2024 by CEO Jeff Dachis, One Health Biosensing leverages over a decade of research and development to address the challenges faced by individuals with type 2 diabetes.

Mission and Vision

The company's mission is to transform the CGM landscape by offering a low-cost, needle-free solution that enhances health outcomes for individuals with diabetes, pre-diabetes, and obesity. Their vision is to make CGM technology accessible to over one billion people, thereby improving global health management.

Industry Significance

The CGM market is valued at approximately $10 billion, with a significant unmet need for affordable and non-invasive monitoring solutions. One Health Biosensing's innovative approach positions it as a potential leader in this growing market, addressing both accessibility and affordability issues.

Key Strategic Focus

Core Objectives

Affordability and Accessibility: Developing a cost-effective CGM device to ensure widespread adoption among individuals with diabetes.

User Experience: Creating a pain-free, needle-free monitoring system that integrates seamlessly into daily life.

Health Outcomes: Utilizing AI-driven insights to improve glycemic control and overall health for users.

Areas of Specialization

Continuous Glucose Monitoring: Focusing on real-time, continuous monitoring of glucose levels to provide actionable health data.

Wearable Health Technology: Designing wearable devices that are comfortable, discreet, and easy to use.

Key Technologies Utilized

Micro-Needle Sensing Platform: Employing a proprietary silicon micro-needle array technology for intradermal glucose sensing.

Artificial Intelligence: Incorporating AI to analyze glucose data and provide personalized health recommendations.

Primary Markets Targeted

Individuals with Type 2 Diabetes: Addressing the needs of over 90% of T2D patients who currently lack access to CGM systems.

Pre-Diabetic and Obese Populations: Offering proactive monitoring solutions to prevent or manage the progression to diabetes.

Financials and Funding

Funding History

As of October 2024, One Health Biosensing has raised approximately $149,766 through a crowdfunding campaign, with a valuation of $20 million.

Recent Funding Rounds

Crowdfunding Campaign: Initiated on October 11, 2024, with a minimum target of $50,000 and a maximum target of $1.24 million.

Notable Investors

The company has attracted investments from prominent venture capital firms, including RRE, Box Group, FJ Labs, True Ventures, and First Round Capital.

Utilization of Capital

The funds raised are intended to support the production of CGM sensors, generate on-body clinical data, and develop factory calibration algorithms.

Pipeline Development

Key Pipeline Candidates

Intradermal CGM Device: A needle-free, micro-needle-based sensor designed for continuous glucose monitoring.

Stages of Development

Clinical Validation: Over 1,500 hours of on-body clinical data have been collected, demonstrating the device's performance and reliability.

Target Conditions

Type 2 Diabetes: Providing continuous monitoring solutions to enhance glycemic control.

Pre-Diabetes and Obesity: Offering early detection and management tools to prevent the onset of diabetes.

Anticipated Milestones

FDA Submission: Plans to submit the device for FDA approval in 2026.

Technological Platform and Innovation

Proprietary Technologies

Silicon Micro-Needle Array: A novel technology enabling painless, intradermal glucose sensing without the need for traditional needles.

Significant Scientific Methods

AI-Driven Data Analysis: Utilizing machine learning algorithms to interpret glucose data and provide personalized health insights.

Leadership Team

Jeffrey Dachis – CEO

Professional Background: Founder and CEO of One Drop, a diabetes management system; co-founder of Razorfish, a web development company acquired by Microsoft.

Contributions: Bringing extensive experience in health-tech entrepreneurship and a proven track record in scaling health-focused startups.

Dan Goldner – CTO

Professional Background: Expert in medical device development with a focus on wearable health technologies.

Contributions: Leading the technological development of One Health Biosensing's CGM device, ensuring innovation and functionality.

Competitor Profile

Market Insights and Dynamics

The global CGM market is experiencing significant growth, driven by the increasing prevalence of diabetes and the demand for continuous health monitoring solutions. However, high costs and invasiveness of existing devices have created a substantial gap in the market for affordable and user-friendly alternatives.

Competitor Analysis

Dexcom: A leading provider of CGM systems, known for its Dexcom G7 sensor.

Abbott Laboratories: Offers the FreeStyle Libre series, a popular CGM device.

Medtronic: Provides the Guardian series of CGM systems.

These competitors have established market presence but often face criticism regarding cost and user comfort, presenting an opportunity for One Health Biosensing to differentiate itself.

Strategic Collaborations and Partnerships

While specific partnerships are not detailed, the company's innovative approach and experienced leadership team position it well for potential collaborations with healthcare providers, technology firms, and research institutions to enhance product development and market reach.

Operational Insights

One Health Biosensing's focus on affordability, user experience, and technological innovation provides a competitive edge in the CGM market. By addressing the limitations of existing devices, the company aims to capture a significant share of the market, particularly among individuals currently without access to CGM technology.

Strategic Opportunities and Future Directions

Strategic Roadmap

Product Development: Finalize the CGM device design and conduct comprehensive clinical trials to validate performance.

Regulatory Approval: Prepare for FDA submission in 2026, aiming for approval and market entry.

Market Expansion: Develop strategies to scale production and distribution, targeting both domestic and international markets.

Future Business Directions

Explore additional health monitoring applications beyond glucose sensing, leveraging the core technology platform to address other chronic health conditions.

Opportunities for Expansion

Potential partnerships with healthcare providers and insurers could facilitate broader adoption of the CGM device, integrating it into standard diabetes care protocols.

Positioning for Future Objectives

The company's commitment to affordability, user-centric design, and technological innovation positions it to meet the growing demand for accessible health monitoring solutions, paving the way for future success in the health-tech industry.